A comprehensive expert review argues that the rise of GLP-1 medications represents a turning point in the treatment of obesity and metabolic disease, extending well beyond their effects on body weight.
According to the review, the success of drugs such as semaglutide and tirzepatide signals a paradigm shift in how clinicians understand and treat metabolic conditions. The authors say the benefits reflect changes in the underlying biology of appetite, blood sugar regulation and energy balance rather than weight loss alone.
Semaglutide, sold under brand names including Ozempic and Wegovy, and tirzepatide mimic gut hormones that influence hunger and insulin response. Clinical trials have shown substantial weight reduction along with improvements in markers tied to cardiovascular and metabolic health.
The review frames these therapies as the start of a new era in which obesity is treated as a chronic medical condition with pharmacological tools, similar to hypertension or diabetes. The authors note growing interest in the drugs’ potential effects on conditions ranging from heart disease to kidney function.
The authors also caution that questions remain about long-term use, cost, access and side effects, underscoring the need for continued study as the medications become more widely prescribed.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/